Dupilumab as a novel steroid-sparing treatment for hypereosinophilic syndrome
Saved in:
Main Authors: | Xiaoman Du, MD (Author), Yudi Chen, MD (Author), Jianmin Chang, MD (Author), Xuelin Sun, MD, PhD (Author), Yue Zhang, MS (Author), Meng Zhang, BM (Author), Marcus Maurer, MD, PhD (Author), Yanming Li, MD (Author), Zuotao Zhao, MD, PhD (Author), Xunliang Tong, MD, PhD (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exacerbation of IgA nephropathy in a patient receiving dupilumab
by: Masako Yamamoto, MD, et al.
Published: (2022) -
The dermatologic and histologic spectrum of hypereosinophilic syndrome
by: Calista Long, BS, et al.
Published: (2023) -
Vitiligo during dupilumab therapy
by: Vincenzo Picone, MD, et al.
Published: (2023) -
Onychodystrophy associated with dupilumab therapy for atopic dermatitis
by: Amanda E. Zubek, MD, PhD, et al.
Published: (2021) -
Treatment of lichen sclerosus and hypertrophic scars with dupilumab
by: Danielle M. Peterson, MD, et al.
Published: (2022)